HRS-4642 combined with nimotuzumab in the treatment of recurrent or metastatic pancreatic ductal adenocarcinoma: study protocol of a single-arm, prospective phase Ib/II trial
This study protocol has been approved by the Ethics Committee of West China Hospital [2024 (2239)].
Authors
- Xin Wang (ORCID: https://orcid.org/0009-0007-5146-2570)
- Pei Zhang (ORCID: https://orcid.org/0000-0003-4331-6622)
- Dan Cao (ORCID: https://orcid.org/0000-0002-3331-823X)
- Qingqing Leng (ORCID: https://orcid.org/0009-0004-5182-2036)
- Huanji Xu (ORCID: https://orcid.org/0000-0003-0314-5646)
- Jitao Zhou (ORCID: https://orcid.org/0000-0002-2173-5773)
Institutions
- Sichuan University (CN)
- Sichuan Cancer Hospital (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-07-04
- DOI
- https://doi.org/10.3389/fphar.2025.1562481
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00